This paper is only available as a PDF. To read, Please Download here.
Advances in supportive care have been among the most influential changes in cancer
treatments over the past few years. Effective anti-emetic therapy has markedly reduced
suffering due to emesis and has allowed most chemotherapy to be delivered on an outpatient
basis. Carefully designed studies have combined knowledge of clinical aspects of chemotherapy
treatment with relevant neuropharmacological considerations. This has permitted the
continued development of new agents and combination regimens, resulting in better
emetic control with fewer side-effects and optimal patient and staff convenience.
Today, the most extensively used anti-emetic agents for patients receiving moderately
to severely emetogenic chemotherapy are the 5-hydroxytryptamine (5-HT3) receptor antagonists. Currently available agents in this therapeutic class include
ondansetron, granisetron, and tropisetron; dolasetron, another member of this class,
is available in the U.K. and is now approvable in the U.S.A. Use of the best proven
regimens prevents both acute and delayed emesis in most patients. In patients receiving
cisplatin, 75–85% achieve complete control of acute emesis and 50–75% have complete
control of delayed emesis. In patients receiving moderately emetogenic chemotherapy,
complete control of acute emesis is achieved by 90% of patients and complete control
of delayed emesis by 80–95% of patients. The most effective and convenient regimens
for acute emesis employ a combination of serotonin antagonists with corticosteroids,
single-dose schedules, the lowest effective doses and, most recently, oral administration.
Further improvement of emetic control will require more widespread adherence to the
best established regimens and identification of other pharmacological pathways.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis.Cancer Treat Rep. 1980; 64: 219-224
- Anti-emetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.N Engl J Med. 1981; 305: 905-909
- Double-blind placebo-controlled study of metoclopramide in cisplatin-induced emesis.N Engl J Med. 1982; 307: 250-251
- Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study.Ann Intern Med. 1990; 113: 834-840
- Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis.J Clin Oncol. 1995; 13: 1242-1248
- Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer.J Clin Oncol. 1996; 14: 2242-2249
- A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.Eur J Cancer. 1996; 32A: 807-813
- Dose ranging evaluation of the serotonin antagonist GR-507/75 (GR38032F) when used as an antiemetic in patients receiving cancer chemotherapy.J Clin Oncol. 1988; 6: 659-662
- Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin.J Natl Cancer Inst. 1989; 81: 42-46
- (abstract)Electrocardiographic changes with serotonin antagonist antiemetics: rate of occurrence and clinical relevance.in: Proc Am Soc Clin Oncol. 12. 1993: 463
- Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydramine. Results of consecutive trials in 255 patients.Cancer. 1985; 55: 527-534
- Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer.N Engl J Med. 1995; 332: 1-5
- (abstract)Ondansetron vs granisetron, both combined with dexamethasone in the prevention of cisplatin-induced emesis.in: Proc Am Soc Clin Oncol. 14. 1995: 523
- Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone.J Clin Oncol. 1991; 9: 674-678
- (abstract)Contribution of dexamethasone to antiemetic control with granisetron is greatest in patients at high risk of emesis.in: Proc Am Soc Clin Oncol. 13. 1994: 436
- Antiemetic control and prevention of side effects of anticancer therapy with lorazepam or diphenhydramine when used in conjunction with metolopramide plus dexamethasone. A double-blind, randomized trial.Cancer. 1987; 69: 1353-1357
- Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol.Cancer Treat Rep. 1984; 68: 163-172
- (abstract)Randomized double blind comparison of delta-9-tetrahydrocannabinol (THC) and marijuana as chemotherapy antiemetics.in: Proc Am Soc Clin Oncol. 3. 1984: 91
- Comparison of the antiemetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomized, parallel group study.Br J Cancer. 1992; 66: 192-197
- Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicenter double-blind, randomized, parallel-group study.Oncology. 1994; 5: 113-118
- Stratified, randomized, double-blind comparison of intravenous dose regimes in the prevention of cisplatin-induced nausea and vomiting.J Clin Oncol. 1992; 10: 1969-1975
- Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis.J Clin Oncol. 1995; 13: 1036-1043
- A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.Cancer Chemother Pharmacol. 1996; 38: 323-328
- Dose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide.Support Care Cancer. 1996; 4: 141-146
Kasimis BS, Tapazoglou E, Schulman P, Stewart WH, Hahne WF, Cramer MB. A double-blind, randomized study of two different dose regimens of intravenous dolaestron in patients receiving high-dose cisplatin chemotherapy. Cancer Invest, in press.
- Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.J Clin Oncol. 1994; 12: 1045-1049
- Antiemetic efficacy of two different single intravenous doses of dolasetron in patients receiving high-dose cisplatin-containing chemotherapy.Am J Clin Oncol. 1996; 19: 619-623
- Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic.Drugs. 1993; 46: 925-943
- Incidence, course, and severity of delayed nausea and vomiting following the administratlon of high-dose cisplatin.J Clin Oncol. 1985; 3: 1379-1384
- Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.J Clin Oncol. 1989; 7: 108-114
- (abstract)Antiemetic trials to control delayed vomiting following high-dose cisplatin.in: Proc Am Soc Clin Oncol. 5. 1986: 257
- (abstract)Management of cisplatin-induced delayed-onset nausea and vomiting: preliminary results with two drug regimens.in: Proc Am Soc Clin Oncol. 4. 1985: 263
- Ondansetron in the prophylaxis of acute and delayed cisplatin-induced emesis.Clin Oncol. 1990; 2: 268-272
- (abstract)Oral ondansetron effectively controls cisplatin-induced delayed emesis.in: Proc Am Soc Clin Oncol. 14. 1995: 523
- Progress in the control of acute and delayed emesis induced by cisplatin.Eur J Cancer. 1991; 27: 509-511
- (abstract)New approaches in preventing delayed emesis: altering the time of regimen initiation and use of combination therapy in a 109-patient trial.in: Proc Am Soc Clin Oncol. 14. 1995: 526
- Behavioral treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy.N Engl J Med. 1982; 307: 1476-1480
- (abstract)A unique all-oral, single-dose, combination antiemetic regimen with high efficacy and marked cost saving potential.in: Proc Am Soc Clin Oncol. 14. 1995: 526
- Day hospital as an alternative to inpatient care for cancer patients: a random assignment trial.J Epidemiol. 1988; 41: 771-785
Article info
Identification
Copyright
© 1997 Published by Elsevier Inc.
